The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Differential Effects of Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor Binding Protein on Fatty-Streak Formation in Apolipoprotein E–Deficient Mice
Abstract
Background —The cytokines interleukin 1 (IL-1) and tumor necrosis factor (TNF) are secreted by the different cell populations of the vascular wall and have been suggested to promote atherosclerosis. Methods and Results —Their respective roles in fatty-streak formation in apolipoprotein E–deficient mice were investigated by use of IL-1 receptor antagonist and TNF binding protein. Estradiol-17β was used as a positive control. Blocking TNF seemed to be active in female animals but not in males. IL-1 receptor antagonist was as effective as or more effective than estradiol in both sexes. Conclusions —IL-1 plays a crucial role in the initial step of the atherosclerotic process in this animal model, and blocking the activity of this cytokine should be considered as a therapeutic possibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plump, A. S., Smith, J. D., Hayek, T., Aalto-Setälä, K., Walsh, A., Verstuyft, J. G., Rubin, E. M., & Breslow, J. L. (1992) · Cell · doi:10.1016/0092-8674(92)90362-g · Cited by 2,263
Cited by
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Tedgui, A., & Mallat, Z. (2006) · Physiological Reviews · doi:10.1152/physrev.00024.2005 · Cited by 1,701
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
Grebe, A., Hoss, F., & Latz, E. (2018) · Circulation Research · doi:10.1161/circresaha.118.311362 · Cited by 926
Changes in Proinflammatory Cytokine Activity after Menopause
Pfeilschifter, J., Köditz, R., Pfohl, M., & Schatz, H. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0456 · Cited by 914
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
The balance between IL-1 and IL-1Ra in disease
Arend, W. P. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00020-5 · Cited by 721
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
Libby, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.028 · Cited by 619
Cytokines and atherosclerosis: a comprehensive review of studies in mice
Kleemann, R., Zadelaar, S., & Kooistra, T. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn120 · Cited by 606
Recent Advances on the Role of Cytokines in Atherosclerosis
Ait-Oufella, H., Taleb, S., Mallat, Z., & Tedgui, A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207415 · Cited by 578
Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.185 · Cited by 477
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
Ramji, D. P., & Davies, T. S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.04.003 · Cited by 469
A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation?
Wen, H., Ting, J. P.-Y., & O'Neill, L. A. J. (2012) · Nature Immunology · doi:10.1038/ni.2228 · Cited by 457
Anti-Inflammatory Mechanisms in the Vascular Wall
Tedgui, A., & Mallat, Z. (2001) · Circulation Research · doi:10.1161/hh0901.090440 · Cited by 422
Role of Monocytes in Atherogenesis
ØSTERUD, B., & BJØRKLID, E. (2003) · Physiological Reviews · doi:10.1152/physrev.00005.2003 · Cited by 412
TNFα in atherosclerosis, myocardial ischemia/reperfusion and heart failure
Kleinbongard, P., Heusch, G., & Schulz, R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.05.002 · Cited by 409
The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease
Zhang, H., & Dhalla, N. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021082 · Cited by 385
de Zoete, M. R., Palm, N. W., Zhu, S., & Flavell, R. A. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016287 · Cited by 379
Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study
Pankow, J. S., Folsom, A. R., Cushman, M., Borecki, I. B., Hopkins, P. N., Eckfeldt, J. H., & Tracy, R. P. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00586-4 · Cited by 375
Erratum: Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.33 · Cited by 363
Morton, A. C., Rothman, A. M. K., Greenwood, J. P., Gunn, J., Chase, A., Clarke, B., Hall, A. S., Fox, K., Foley, C., Banya, W., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu272 · Cited by 353
van der Heijden, T., Kritikou, E., Venema, W., van Duijn, J., van Santbrink, P. J., Slütter, B., Foks, A. C., Bot, I., & Kuiper, J. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309575 · Cited by 348
“Mice lacking either NLRP3 or IL-1β display reduced atherosclerosis, and blockade of the IL-1 receptor results in decreased lesion size.(7,9,14) Therefore, inhibition of the NLRP3 inflammasome could be a potential therapeutic strategy to treat atherosclerosis.”
Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity
Donath, M. Y., Dalmas, É., Sauter, N. S., & Böni-Schnetzler, M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.001 · Cited by 338
Ohta, H., Wada, H., Niwa, T., Kirii, H., Iwamoto, N., Fujii, H., Saito, K., Sekikawa, K., & Seishima, M. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.11.016 · Cited by 334
The role of cytokines in the development of atherosclerosis
Fatkhullina, A. R., Peshkova, I. O., & Koltsova, E. K. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916110134 · Cited by 323
Koenig, W. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.113 · Cited by 315
The role of IL-1 in the pathogenesis of heart disease
Bujak, M., & Frangogiannis, N. G. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0024-y · Cited by 307
Freigang, S., Ampenberger, F., Spohn, G., Heer, S., Shamshiev, A. T., Kisielow, J., Hersberger, M., Yamamoto, M., Bachmann, M. F., & Kopf, M. (2011) · European Journal of Immunology · doi:10.1002/eji.201041316 · Cited by 300
Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification
Doherty, T. M., Fitzpatrick, L. A., Inoue, D., Qiao, J.-H., Fishbein, M. C., Detrano, R. C., Shah, P. K., & Rajavashisth, T. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0015 · Cited by 299
The Inflammasomes and Autoinflammatory Syndromes
Broderick, L., De Nardo, D., Franklin, B. S., Hoffman, H. M., & Latz, E. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040431 · Cited by 295
van Diepen, J. A., Berbée, J. F. P., Havekes, L. M., & Rensen, P. C. N. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.02.028 · Cited by 292
Osteoporosis and Cardiovascular Disease: Brittle Bones and Boned Arteries, Is There a Link?
McFarlane, S. I., Muniyappa, R., Shin, J. J., Bahtiyar, G., & Sowers, J. R. (2004) · Endocrine · doi:10.1385/endo:23:1:01 · Cited by 289
IL-1 receptor 2 (IL-1R2) and its role in immune regulation
Peters, V. A., Joesting, J. J., & Freund, G. G. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.11.006 · Cited by 264
Targeting Interleukin-1β Reduces Leukocyte Production After Acute Myocardial Infarction
Sager, H. B., Heidt, T., Hulsmans, M., Dutta, P., Courties, G., Sebas, M., Wojtkiewicz, G. R., Tricot, B., Iwamoto, Y., Sun, Y., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.016160 · Cited by 253
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Rajamäki, K., Mäyränpää, M. I., Risco, A., Tuimala, J., Nurmi, K., Cuenda, A., Eklund, K. K., Öörni, K., & Kovanen, P. T. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.307312 · Cited by 75
Billon, C., Canaple, L., Fleury, S., Deloire, A., Beylot, M., Dombrowicz, D., del Carmine, P., Samarut, J., & Gauthier, K. (2014) · Endocrinology · doi:10.1210/en.2014-1098 · Cited by 45
“2740 Billon et al TR Protects Against Atherosclerosis Endocrinology, July 2014, 155(7):2735–2745”
BackgroundInfluential
Metadata
- Authors
- Elhage, R., Maret, A., Pieraggi, M.-T., Thiers, J. C., Arnal, J. F., & Bayard, F.
- Venue
- Circulation
- Published
- 1998-01-27
- Volume
- 97
- Issue
- 3
- Pages
- 242-244
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1975532423
- Cited by
- 209
- References
- 1
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.